Series B · Biotech · Liège, Belgium · 11–50 employees
Imcyse is a Liège-based clinical-stage biopharmaceutical company pioneering active specific immunotherapies (Imotopes™) to treat and potentially cure severe autoimmune diseases such as type 1 diabetes and multiple sclerosis by precisely modulating the immune response; it completed a major Series B financing in June 2019 to advance its pipeline and has ongoing Phase 1/2 clinical programmes.
No open roles listed right now.